Trials / Completed
CompletedNCT01076205
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Rheumatoid Arthritis Under HUMIRA® (Adalimumab) in Routine Clinical Practice (AGIL)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,229 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The AGIL study was designed to evaluate the effectiveness and safety of adalimumab over 5 years in routine daily clinical practice in Germany, with a focus on the impact of therapy on employment-related outcomes.
Conditions
Timeline
- Start date
- 2009-01-12
- Primary completion
- 2017-09-14
- Completion
- 2017-09-14
- First posted
- 2010-02-26
- Last updated
- 2019-02-07
- Results posted
- 2019-02-07
Source: ClinicalTrials.gov record NCT01076205. Inclusion in this directory is not an endorsement.